Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Iris Chan, M.D., Ph.D.
Genentech, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Facility name not stated
Baltimore, Maryland, United States
- Facility name not stated
Boston, Massachusetts, United States
- Facility name not stated
Boston, Massachusetts, United States
- Facility name not stated
Detroit, Michigan, United States
- Facility name not stated
Oklahoma City, Oklahoma, United States
- Facility name not stated
Nashville, Tennessee, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Nov 2009
- Primary completion
- 31 Mar 2014
- Completion
- 31 Mar 2014
- Last update posted
- 30 Dec 2016
- Registered enrollment
- 178
- Registry id
- NCT00996892
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.